2.37
+0.04(+1.72%)
Currency In USD
| Previous Close | 2.33 |
| Open | 2.35 |
| Day High | 2.41 |
| Day Low | 2.33 |
| 52-Week High | 11.03 |
| 52-Week Low | 1.69 |
| Volume | 63,175 |
| Average Volume | 87,172 |
| Market Cap | 7.44M |
| PE | -0.89 |
| EPS | -2.67 |
| Moving Average 50 Days | 2.21 |
| Moving Average 200 Days | 3.31 |
| Change | 0.04 |
If you invested $1000 in Alzamend Neuro, Inc. (ALZN) since IPO date, it would be worth $0.13 as of January 14, 2026 at a share price of $2.37. Whereas If you bought $1000 worth of Alzamend Neuro, Inc. (ALZN) shares 3 years ago, it would be worth $2.79 as of January 14, 2026 at a share price of $2.37.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
GlobeNewswire Inc.
Jul 28, 2025 12:00 PM GMT
Session Topic is the Innovation and Current Directions in Military Suicide Prevention, Research, and ProgramsPresentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate ATLANTA
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
GlobeNewswire Inc.
Jul 23, 2025 12:00 PM GMT
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 millionStockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cashIn May 2025, Alzamend dosed the first patient for the healthy human p
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
GlobeNewswire Inc.
Jun 16, 2025 12:00 PM GMT
Capital Raised to Support Five Clinical TrialsATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheime